A new SEC filing for Thermo Fisher Scientific Inc. (TMO) was recorded as of 1 August 2026, prompting renewed examination of the company's financial and ownership profile [Brief - 2026-08-01]. No additional briefing disclosures beyond that filing date were available for the current reporting period [Brief - 2026-08-09].
Thermo Fisher's trailing twelve-month revenue stood at $46.34 billion as of 27 June 2026, representing year-over-year growth of approximately 10.5% [SEC 10-Q - TMO - 2026-06-27]. Net income on a TTM basis reached $6.98 billion, with a net margin of 15.07% and an operating margin of 17.58%. Gross margin was recorded at 24.45%. EPS grew 9.35% year-over-year. The company held $4.06 billion in cash against total debt of $45.65 billion. The price-to-earnings ratio stood at 31.65 [SEC 10-Q - TMO - 2026-06-27].
Insider activity over the past 30 days reflected a net selling direction, with 79 transactions recorded and a net disposal value of approximately $39.27 million [SEC Form 4 - TMO - 2026-08]. On the institutional side, five significant managers opened new positions in TMO during the most recent reporting period: Citadel (Ken Griffin), D1 Capital (Dan Sundheim), Millennium (Izzy Englander), AQR Capital (Cliff Asness), and Bridgewater (Ray Dalio) each initiated new holdings [SEC 13F - Citadel - Q2 2026] [SEC 13F - D1Capital - Q2 2026] [SEC 13F - Millennium - Q2 2026] [SEC 13F - AQRCapital - Q2 2026] [SEC 13F - Bridgewater - Q2 2026]. These simultaneous new positions across multiple large institutional managers constitute the primary trigger for this report.
The prevailing macroeconomic backdrop includes a 10-year US Treasury yield of 4.63% and a 2-year yield of 4.15%, producing a normal yield curve spread of 48 basis points [FRED DGS10] [FRED DGS2]. This configuration reflects the broader fixed-income environment in which large-capitalisation equities such as TMO are currently being assessed by market participants.